Phase II Study of Pemigatinib in Patients With Adenosquamous Carcinoma of the Pancreas
Summary
The purpose of this phase II study is to evaluate the safety and efficacy of pemigatinib in patients with advanced or surgically unresectable adenosquamous carcinoma of the pancreas who have progressed on previous therapy.
General Information
NCT#: NCT05216120
Study ID: Incyte-54828-19-05
Trial Phase: Phase II
Trial Sponsor: HonorHealth Research Institute
Therapies Used in This Trial: Pemigatinib